Drug intelligence / Profile preview

CYC156

Development stage: Unknown
Lead developer: Totient
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**CYC156** is a monoclonal antibody that binds to cancer/testis antigen 1 (CTAG1, also known as NY-ESO-1), a protein normally expressed only in testicular germ cells but aberrantly expressed in various cancers including those of the skin, uterus, and bladder. Identified through deorphaning studies using Membrane Proteome Array (MPA) technology, it demonstrates high-affinity binding to CTAG1, suggesting potential as a cancer therapeutic targeting tumors with this antigen. Developed by Totient (now part of Integral Molecular), it was derived from cancerous tissues and validated via biosensor experiments for binding kinetics.[4]

Other names: CYC187CYC-187CYC 187

Targets

NY-ESO-1 (New york esophageal squamous cell carcinoma 1)

Beyond the preview

Go deeper on CYC156.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYC156.

Explore the full profile